Literature DB >> 30633371

ARB Superiority Over ACE Inhibitors in Coronary Heart Disease: An Alternative Viewpoint.

Steven M Smith1,2, Jimin Lee3, Sukhyang Lee3.   

Abstract

Entities:  

Keywords:  ACE inhibitors; angiotensin receptor blocker; coronary heart disease; epidemiology; study design

Mesh:

Substances:

Year:  2019        PMID: 30633371      PMCID: PMC6469961          DOI: 10.1002/phar.2216

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


× No keyword cloud information.
  7 in total

1.  Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.

Authors:  Jun Cheng; Wen Zhang; Xiaohui Zhang; Fei Han; Xiayu Li; Xuelin He; Qun Li; Jianghua Chen
Journal:  JAMA Intern Med       Date:  2014-05       Impact factor: 21.873

Review 2.  Immortal time bias in pharmaco-epidemiology.

Authors:  Samy Suissa
Journal:  Am J Epidemiol       Date:  2007-12-03       Impact factor: 4.897

Review 3.  Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.

Authors:  Edmond C K Li; Balraj S Heran; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2014-08-22

4.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

5.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

6.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

7.  Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.

Authors:  Jimin Lee; Sukhyang Lee
Journal:  Pharmacotherapy       Date:  2018-10-21       Impact factor: 4.705

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.